{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:15:36Z","timestamp":1790964936380,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T00:00:00Z","timestamp":1518134400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T00:00:00Z","timestamp":1518134400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA016087"],"award-info":[{"award-number":["P30 CA016087"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["S10 OD01058"],"award-info":[{"award-number":["S10 OD01058"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["S10 OD018338"],"award-info":[{"award-number":["S10 OD018338"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s11060-018-2788-6","type":"journal-article","created":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T09:35:40Z","timestamp":1518168940000},"page":"183-190","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":73,"title":["Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors"],"prefix":"10.1007","volume":"138","author":[{"given":"Shiyang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Liechty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis J.","family":"Hollmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matija","family":"Snuderl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias A.","family":"Karajannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,9]]},"reference":[{"key":"2788_CR1","doi-asserted-by":"publisher","first-page":"17004","DOI":"10.1038\/nrdp.2017.4","volume":"3","author":"DH Gutmann","year":"2017","unstructured":"Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL, Johnson KJ (2017) Neurofibromatosis type 1. Nat Rev Dis Primers 3:17004. \n                    https:\/\/doi.org\/10.1038\/nrdp.2017.4","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"2788_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1177\/0883073816666736","volume":"32","author":"S Ardern-Holmes","year":"2017","unstructured":"Ardern-Holmes S, Fisher G, North K (2017) Neurofibromatosis type 2. J Child Neurol 32(1):9\u201322. \n                    https:\/\/doi.org\/10.1177\/0883073816666736","journal-title":"J Child Neurol"},{"issue":"1","key":"2788_CR3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/MOP.0000000000000169","volume":"27","author":"MA Karajannis","year":"2015","unstructured":"Karajannis MA, Ferner RE (2015) Neurofibromatosis-related tumors: emerging biology and therapies. Curr Opin Pediatr 27(1):26\u201333. \n                    https:\/\/doi.org\/10.1097\/MOP.0000000000000169","journal-title":"Curr Opin Pediatr"},{"key":"2788_CR4","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1146\/annurev-pathol-052016-100228","volume":"12","author":"CL Monroe","year":"2017","unstructured":"Monroe CL, Dahiya S, Gutmann DH (2017) Dissecting clinical heterogeneity in neurofibromatosis type 1. Annu Rev Pathol 12:53\u201374. \n                    https:\/\/doi.org\/10.1146\/annurev-pathol-052016-100228","journal-title":"Annu Rev Pathol"},{"key":"2788_CR5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/82_2017_67","volume":"410","author":"K Chamoto","year":"2017","unstructured":"Chamoto K, Al-Habsi M, Honjo T (2017) Role of PD-1 in immunity and diseases. Curr Top Microbiol Immunol 410:75\u201397. \n                    https:\/\/doi.org\/10.1007\/82_2017_67","journal-title":"Curr Top Microbiol Immunol"},{"key":"2788_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2017-204853","author":"A Kythreotou","year":"2017","unstructured":"Kythreotou A, Siddique A, Mauri FA, Bower M, Pinato DJ (2017) PD-L1. J Clin Pathol. \n                    https:\/\/doi.org\/10.1136\/jclinpath-2017-204853","journal-title":"J Clin Pathol"},{"issue":"3","key":"2788_CR7","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/annonc\/mdv615","volume":"27","author":"J Chen","year":"2016","unstructured":"Chen J, Jiang CC, Jin L, Zhang XD (2016) Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Ann Oncol 27(3):409\u2013416. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdv615","journal-title":"Ann Oncol"},{"key":"2788_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2017-135187","author":"X Wang","year":"2017","unstructured":"Wang X, Huang S, Zhang Y, Zhu L, Wu X (2017) The application and mechanism of PD pathway blockade for cancer therapy. Postgrad Med J. \n                    https:\/\/doi.org\/10.1136\/postgradmedj-2017-135187","journal-title":"Postgrad Med J"},{"issue":"5","key":"2788_CR9","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00262-017-1954-6","volume":"66","author":"AV Balar","year":"2017","unstructured":"Balar AV, Weber JS (2017) PD-1 and PD-L1 antibodies in cancer: current status and future directions. Cancer Immunol Immunother 66(5):551\u2013564. \n                    https:\/\/doi.org\/10.1007\/s00262-017-1954-6","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"2788_CR10","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2174\/1568010054022024","volume":"4","author":"N Fujiwara","year":"2005","unstructured":"Fujiwara N, Kobayashi K (2005) Macrophages in inflammation. Curr Drug Targets Inflamm Allergy 4(3):281\u2013286","journal-title":"Curr Drug Targets Inflamm Allergy"},{"issue":"1","key":"2788_CR11","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00401-012-1056-7","volume":"125","author":"CE Prada","year":"2013","unstructured":"Prada CE, Jousma E, Rizvi TA, Wu J, Dunn RS, Mayes DA, Cancelas JA, Dombi E, Kim MO, West BL, Bollag G, Ratner N (2013) Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition. Acta Neuropathol. 125(1):159\u2013168. \n                    https:\/\/doi.org\/10.1007\/s00401-012-1056-7","journal-title":"Acta Neuropathol"},{"issue":"4","key":"2788_CR12","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.devcel.2016.09.027","volume":"39","author":"Y Shi","year":"2016","unstructured":"Shi Y, Bollam SR, White SM, Laughlin SZ, Graham GT, Wadhwa M, Chen H, Nguyen C, Vitte J, Giovannini M, Toretsky J, Yi C (2016) Rac1-mediated DNA damage and inflammation promote Nf2 tumorigenesis but also limit cell-cycle progression. Dev Cell 39(4):452\u2013465. \n                    https:\/\/doi.org\/10.1016\/j.devcel.2016.09.027","journal-title":"Dev Cell"},{"key":"2788_CR13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/1741-7015-11-109","volume":"11","author":"SJ Park","year":"2013","unstructured":"Park SJ, Sawitzki B, Kluwe L, Mautner VF, Holtkamp N, Kurtz A (2013) Serum biomarkers for neurofibromatosis type 1 and early detection of malignant peripheral nerve-sheath tumors. BMC Med 11:109. \n                    https:\/\/doi.org\/10.1186\/1741-7015-11-109","journal-title":"BMC Med"},{"issue":"15","key":"2788_CR14","first-page":"4507","volume":"62","author":"H Li","year":"2002","unstructured":"Li H, Velasco-Miguel S, Vass WC, Parada LF, DeClue JE (2002) Epidermal growth factor receptor signaling pathways are associated with tumorigenesis in the Nf1:p53 mouse tumor model. Cancer Res 62(15):4507\u20134513","journal-title":"Cancer Res"},{"issue":"4","key":"2788_CR15","doi-asserted-by":"publisher","first-page":"4251","DOI":"10.1007\/s13277-016-4812-9","volume":"37","author":"ZY Dong","year":"2016","unstructured":"Dong ZY, Wu SP, Liao RQ, Huang SM, Wu YL (2016) Potential biomarker for checkpoint blockade immunotherapy and treatment strategy. Tumour Biol 37(4):4251\u20134261. \n                    https:\/\/doi.org\/10.1007\/s13277-016-4812-9","journal-title":"Tumour Biol"},{"issue":"12","key":"2788_CR16","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1158\/2326-6066.CIR-15-0116","volume":"3","author":"KM Mahoney","year":"2015","unstructured":"Mahoney KM, Sun H, Liao X, Hua P, Callea M, Greenfield EA, Hodi FS, Sharpe AH, Signoretti S, Rodig SJ, Freeman GJ (2015) PD-L1 antibodies to its cytoplasmic domain most clearly delineate cell membranes in immunohistochemical staining of tumor cells. Cancer Immunol Res 3(12):1308\u20131315. \n                    https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0116","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"2788_CR17","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1097\/MAO.0b013e3181e40e4f","volume":"31","author":"DJ Archibald","year":"2010","unstructured":"Archibald DJ, Neff BA, Voss SG, Splinter PL, Driscoll CL, Link MJ, Dong H, Kwon ED (2010) B7-H1 expression in vestibular schwannomas. Otol Neurotol 31(6):991\u2013997. \n                    https:\/\/doi.org\/10.1097\/MAO.0b013e3181e40e4f","journal-title":"Otol Neurotol"},{"issue":"3","key":"2788_CR18","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s11060-016-2256-0","volume":"130","author":"SJ Han","year":"2016","unstructured":"Han SJ, Reis G, Kohanbash G, Shrivastav S, Magill ST, Molinaro AM, McDermott MW, Theodosopoulos PV, Aghi MK, Berger MS, Butowski NA, Barani I, Phillips JJ, Perry A, Okada H (2016) Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma. J Neurooncol 130(3):543\u2013552. \n                    https:\/\/doi.org\/10.1007\/s11060-016-2256-0","journal-title":"J Neurooncol"},{"issue":"3","key":"2788_CR19","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.cell.2008.08.041","volume":"135","author":"FC Yang","year":"2008","unstructured":"Yang FC, Ingram DA, Chen S, Zhu Y, Yuan J, Li X, Yang X, Knowles S, Horn W, Li Y, Zhang S, Yang Y, Vakili ST, Yu M, Burns D, Robertson K, Hutchins G, Parada LF, Clapp DW (2008) Nf1-dependent tumors require a microenvironment containing Nf1+\/-- and c-kit-dependent bone marrow. Cell 135(3):437\u2013448. \n                    https:\/\/doi.org\/10.1016\/j.cell.2008.08.041","journal-title":"Cell"},{"issue":"10","key":"2788_CR20","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.neo.2015.10.002","volume":"17","author":"AC Solga","year":"2015","unstructured":"Solga AC, Pong WW, Kim KY, Cimino PJ, Toonen JA, Walker J, Wylie T, Magrini V, Griffith M, Griffith OL, Ly A, Ellisman MH, Mardis ER, Gutmann DH (2015) RNA sequencing of tumor-associated microglia reveals Ccl5 as a stromal chemokine critical for neurofibromatosis-1 glioma growth. Neoplasia 17(10):776\u2013788. \n                    https:\/\/doi.org\/10.1016\/j.neo.2015.10.002","journal-title":"Neoplasia"},{"key":"2788_CR21","first-page":"7302","volume":"9","author":"J Zhao Li","year":"2016","unstructured":"Zhao Li J, Xu X, Liu R, Guo P, Wang (2016) Dysregulation of IL-10 by macrophages and T cells in recurrent and malignant schwannomas. Int J Clin Exp Pathol 9:7302\u20137309","journal-title":"Int J Clin Exp Pathol"},{"issue":"10","key":"2788_CR22","doi-asserted-by":"publisher","first-page":"3656","DOI":"10.1182\/blood-2002-03-0734","volume":"100","author":"DA Ingram","year":"2002","unstructured":"Ingram DA, Zhang L, McCarthy J, Wenning MJ, Fisher L, Yang FC, Clapp DW, Kapur R (2002) Lymphoproliferative defects in mice lacking the expression of neurofibromin: functional and biochemical consequences of Nf1 deficiency in T-cell development and function. Blood 100(10):3656\u20133662","journal-title":"Blood"},{"issue":"7","key":"2788_CR23","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1158\/1078-0432.CCR-14-2339","volume":"21","author":"L Liu","year":"2015","unstructured":"Liu L, Mayes PA, Eastman S, Shi H, Yadavilli S, Zhang T, Yang J, Seestaller-Wehr L, Zhang SY, Hopson C, Tsvetkov L, Jing J, Zhang S, Smothers J, Hoos A (2015) The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4. Clin Cancer Res 21(7):1639\u20131651. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2339","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2788_CR24","first-page":"881","volume":"29","author":"J Wada","year":"2009","unstructured":"Wada J, Suzuki H, Fuchino R, Yamasaki A, Nagai S, Yanai K, Koga K, Nakamura M, Tanaka M, Morisaki T, Katano M (2009) The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions. Anticancer Res 29(3):881\u2013888","journal-title":"Anticancer Res"},{"key":"2788_CR25","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s00262-007-0441-x","volume":"57","author":"T Osada","year":"2008","unstructured":"Osada T, Chong G, Tansik R, Hong T, Spector N, Kumar R, Hurwitz HI, Dev I, Nixon AB, Lyerly HK, Clay T, Morse MA (2008) The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother 57:1115\u20131124. \n                    https:\/\/doi.org\/10.1007\/s00262-007-0441-x","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"2788_CR26","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/nm1517","volume":"13","author":"AT Parsa","year":"2007","unstructured":"Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, Cachola KE, Murray JC, Tihan T, Jensen MC, Mischel PS, Stokoe D, Pieper RO (2007) Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 13(1):84\u201388.\u00a0\n                    https:\/\/doi.org\/10.1038\/nm1517","journal-title":"Nat Med"},{"issue":"2","key":"2788_CR27","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s11060-014-1710-0","volume":"122","author":"S Goutagny","year":"2015","unstructured":"Goutagny S, Raymond E, Esposito-Farese M, Trunet S, Mawrin C, Bernardeschi D, Larroque B, Sterkers O, Giovannini M, Kalamarides M\u00a0(2015)\u00a0Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas.\u00a0J Neurooncol 122(2):313\u2013320. \n                    https:\/\/doi.org\/10.1007\/s11060-014-1710-0","journal-title":"J Neurooncol"},{"issue":"14","key":"2788_CR28","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1200\/JCO.2015.64.3817","volume":"34","author":"JO Blakeley","year":"2016","unstructured":"Blakeley JO, Ye X, Duda DG, Halpin CF, Bergner AL, Muzikansky A, Merker VL, Gerstner ER, Fayad LM, Ahlawat S, Jacobs MA, Jain RK, Zalewski C, Dombi E, Widemann BC, Plotkin SR (2016) Efficacy and biomarker study of bevacizumab for hearing loss resulting from neurofibromatosis type 2-associated vestibular schwannomas. J Clin Oncol 34(14):1669\u20131675. \n                    https:\/\/doi.org\/10.1200\/JCO.2015.64.3817","journal-title":"J Clin Oncol"},{"issue":"26","key":"2788_CR29","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","volume":"375","author":"E Dombi","year":"2016","unstructured":"Dombi E, Baldwin A, Marcus LJ, Fisher MJ, Weiss B, Kim A, Whitcomb P, Martin S, Aschbacher-Smith LE, Rizvi TA, Wu J, Ershler R, Wolters P, Therrien J, Glod J, Belasco JB, Schorry E, Brofferio A, Starosta AJ, Gillespie A, Doyle AL, Ratner N, Widemann BC (2016) Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. N Engl J Med 375(26):2550\u20132560. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1605943","journal-title":"N Engl J Med"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-018-2788-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-018-2788-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-018-2788-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T07:30:11Z","timestamp":1589700611000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-018-2788-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,9]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["2788"],"URL":"https:\/\/doi.org\/10.1007\/s11060-018-2788-6","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,9]]},"assertion":[{"value":"16 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}